Award given for saving millions of lives by providing sustained access to childhood vaccines around the globe

Geneva, 10 September 2019 – The Albert and Mary Lasker Foundation announced today that Gavi, the Vaccine Alliance has received the prestigious 2019 Lasker~Bloomberg Public Service Award for providing sustained access to childhood vaccines in the world’s poorest countries, saving millions of lives and highlighting the power of immunisation to prevent diseases.

“It is a great honour for us to receive such a prestigious Award,” said Dr Seth Berkley, CEO of Gavi the Vaccine Alliance. “Since its creation in 2000 at Davos, Gavi has been making it possible for the world’s most vulnerable children to receive the vaccines they need to live healthy, successful lives. Our collective work as an Alliance has prevented more than 13 million deaths in developing countries while child mortality was halved largely thanks to immunisation. I couldn’t be prouder of what we have accomplished together.”

Our collective work as an Alliance has prevented more than 13 million deaths in developing countries while child mortality was halved largely thanks to immunisation. I couldn’t be prouder of what we have accomplished together. 

Dr Seth Berkley

Gavi CEO

Gavi now helps immunise around half the world’s children through a unique public-private partnership that brings together governments, private donors, industry, civil society organisations and international organisations to deliver life-saving vaccination programmes in low-income countries. Driven by country leadership, Gavi offers vaccines at a lower cost while countries take a share of costs and build sustainable immunisation programme before transitioning out of Gavi support.

“On behalf of the hundreds of thousands of vaccinators, health workers and partners that make up our Vaccine Alliance, we are delighted to receive the Lasker~Bloomberg Public Service Award,” said Dr Ngozi Okonjo-Iweala, Chair of the Gavi Board. “All children – regardless of whether they are girls or boys, where they live or how poor they are – have the right to be protected against deadly diseases. However, nearly 20 million children are still missing out on a full course of the most basic vaccines, and more than 10 million do not even receive the first dose. Building on nearly two decades of steady progress, Gavi will redouble efforts in the coming years to extend immunisation services to those communities missed today.”

On behalf of the hundreds of thousands of vaccinators, health workers and partners that make up our Vaccine Alliance, we are delighted to receive the Lasker~Bloomberg Public Service Award.

Dr Ngozi Okonjo-Iweala

Chair of the Gavi Board

Every year since 1945, the Lasker Foundation has presented a range of awards for some of the most accomplished people and institutions involved in breakthrough biological discoveries and clinical health advances. The Lasker~Bloomberg Public Service Award honours exceptional individuals or organisations whose impact on public health or public service has enlarged the possibilities for medical research and the health sciences.

The Lasker Foundation will formally present the Public Service Award to Gavi, the Vaccine Alliance at a ceremony on September 20 in New York City.

Since 2000, Gavi has supported more than 460 vaccine introductions and campaigns, providing funding for vaccine procurement and strengthening health systems. Gavi also funds the global stockpiles of cholera, yellow fever and meningitis vaccines, and supports measles response. Gavi stimulates the dissemination of new vaccines such as the Ebola vaccine that is now being used in the Democratic Republic of the Congo. Gavi is funded through contributions by governments as well as Foundations and the private sector.

The Alliance recently unveiled in Japan its 2021-25 Investment Opportunity calling on donors to back plans to immunise an additional 300 million children in developing countries against deadly diseases, saving a further seven to eight million lives. The replenishment process will culminate in a special event hosted by the UK government, mid-2020.

Notes to editors

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 760 million children – and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at and connect with us on Facebook and Twitter.

The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.

Latest news

View all

18 October 2021

First Portuguese COVAX doses reach Senegal

As part of a pledge to share at least 5% of domestic supply of vaccines with its development partners, the first doses donated by Portugal through COVAX have reached Senegal.

11 October 2021

Vigne des Nations: 2020 vintage awarded to Gavi by Geneva Canton, for its action for global health

This Monday morning, 11 October, Mr Serge Dal Busco, President of the Council of State of Geneva, symbolically awarded the parcel of the Vigne des Nations to Gavi, the Vaccine Alliance. This recognition honours the commitment of this organisation…

11 October 2021

First Swiss-donated doses ship to Sierra Leone, as part of 4 million dose pledge

The first shipment of a Swiss donation of 4 million doses has arrived in Sierra Leone, with 24,000 doses of the AstraZeneca vaccine touching down in Freetown on 9 October 2021.

6 October 2021

Gavi, Unitaid and the Global Fund welcome WHO recommendation for world’s first malaria vaccine

WHO recommendation for wider use of the RTS,S malaria vaccine is largely based on data gathered during malaria vaccine pilots which took place in Kenya, Ghana and Malawi

6 October 2021

Gulf countries unite to support COVAX

Gulf Cooperation Council (GCC) countries have come together to support global equitable access to COVID-19 vaccines, with pledges now totalling US$ 221 million in funding pledges and US$ 50 million in in-kind support from all six Member States,…

30 September 2021

Gavi statement on the report of the independent commission on sexual exploitation and abuse

Geneva, 30 September 2021 – Last year, an Independent Commission was appointed to investigate allegations of sexual exploitation and abuse during the response to the tenth Ebola Virus Disease epidemic in North Kivu and Ituri, in the Democratic…

29 September 2021

Gavi Board meets to discuss routine immunisation, COVAX’s 2022 strategy

The Gavi Board met yesterday to discuss the impact of the pandemic on routine immunisation and how COVAX can best support countries’ efforts to control the pandemic, as part of a broader consultative process to develop the 2022 COVAX strategy

29 September 2021

Gavi progress report shows resilience in childhood vaccinations despite impact of COVID-19 pandemic

In the face of a global pandemic, routine and childhood vaccination has held relatively strong, Gavi’s latest Annual Progress Report shows, with routine immunisations dropping 4% over the course of 2020.

23 September 2021

Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX

Leaders pledge financing, dose donations, support for country readiness and delivery and scale up of global manufacturing, to enable equitable access to COVID-19 vaccines.

Subscribe to our newsletter